AFYX Therapeutics Receives EU Approval for Its Low-Dose Oral Misoprostol Tablet for Induction of Labour in 20 European Countries and Northern Ireland. Hørsholm, Denmark – 4 May 2026 AFYX Therapeutics A/S (“AFYX”), a Danish specialty pharmaceutical company focused on...
PRESS RELEASE AFYX Therapeutics enters strategic partnership with Adcock Ingram Critical Care for distribution in South Africa and Sub-Saharan Africa. Copenhagen, Denmark – January 22, 2026. AFYX Therapeutics has entered a strategic distribution partnership with...
PRESS RELEASE Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment Presented at ESTRO 2025 FOR IMMEDIATE RELEASE – Date: May 5th, 2025 Clinical Study Demonstrates Improved Locoregional Control with Nimorazole...
PRESS RELEASE Hørsholm, Denmark – April 23, 2025 Lunatus and AFYX Therapeutics A/S are pleased to announce a new distribution and sales collaboration for AFYX’s induction of labor product, Gefena (Misoprostol 25μg tablet). Under this agreement, Lunatus will...
PRESS RELEASE In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers...
PRESS RELEASE Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement for France. Hørsholm, Denmark January 13th 2025 – AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing...
